According to a survey carried out in 2020, 94 percent of respondents in Spain were in favor of compulsory vaccinations, the highest share in Europe. Furthermore, almost 90 percent of Finns supported compulsory vaccinations, while the lowest support for this policy was found in Switzerland at 70 percent,

As of January 18, 2023, Portugal had the highest COVID-19 vaccination rate in Europe having administered 272.78 doses per 100 people in the country, while Malta had administered 258.49 doses per 100. The UK was the first country in Europe to approve the Pfizer/BioNTech vaccine for widespread use and began inoculations on December 8, 2020, and so far have administered 224.04 doses per 100. At the latest data, Belgium had carried out 253.89 doses of vaccines per 100 population. Russia became the first country in the world to authorize a vaccine - named Sputnik V - for use in the fight against COVID-19 in August 2020. As of August 4, 2022, Russia had administered 127.3 doses per 100 people in the country.

The seven-day rate of cases across Europe shows an ongoing perspective of which countries are worst affected by the virus relative to their population. For further information about the coronavirus pandemic, please visit our dedicated Facts and Figures page.

This study provides a macro-level societal and health system focused analysis of child vaccination rates in 30 European countries, exploring the effect of context on coverage. The importance of demography and health system attributes on health care delivery are recognized in other fields, but generally overlooked in vaccination. The analysis is based on correlating systematic data built up by the Models of Child Health Appraised (MOCHA) Project with data from international sources, so as to exploit a one-off opportunity to set the analysis within an overall integrated study of primary care services for children, and the learning opportunities of the ‘natural European laboratory’. The descriptive analysis shows an overall persistent variation of coverage across vaccines with no specific vaccination having a low rate in all the EU and EEA countries. However, contrasting with this, variation between total uptake per vaccine across Europe suggests that the challenge of low rates is related to country contexts of either policy, delivery, or public perceptions. Econometric analysis aiming to explore whether some population, policy and/or health system characteristics may influence vaccination uptake provides important results - GDP per capita and the level of the population’s higher education engagement are positively linked with higher vaccination coverage, whereas mandatory vaccination policy is related to lower uptake rates. The health system characteristics that have a significant positive effect are a cohesive management structure; a high nurse/doctor ratio; and use of practical care delivery reinforcements such as the home-based record and the presence of child components of e‑health strategies.

By August 2024, Cuba had administered the largest number of vaccines against COVID-19 per 100 inhabitants in the Latin American region, followed by Chile and Peru. According to recent estimates, the Caribbean country applied around 410 doses per 100 population, accounting for one of the largest vaccination rates observed not only in the Latin American region, but worldwide. In comparison, Haiti registered the lowest vaccination rate within the region, with only 5.87 doses administered per 100 inhabitants. Booster shots started To reinforce the immune protection against the fast spread of the SARS-CoV-2, governments began to introduce booster shots in their immunization programs aiming at strengthening people’s immune response against new contagious COVID-19 variants. In Latin America, Cuba was leading on booster shots relative to its population among a selection of countries, with around 88 percent of the population receiving the extra dose. In comparison, these numbers are higher than those for the European Union and the United States. Pharmaceutical research continues As Omicron becomes more prominent worldwide, and recombinant variants emerge, research efforts to prevent and control the disease continue to progress. As of June 2022, there were around 2,700 clinical trials to treat COVID-19 and 1,752 COVID-19 vaccines trials in clinical development. Other studies were focused on mild, moderate and severe COVID-19, complication support, and post-COVID symptoms, among others.For further information about the coronavirus (COVID-19) pandemic, please visit our dedicated Facts and Figures page.

Following the Great Smallpox Pandemic of the 1870s, many countries in Europe introduced or enforced mandatory vaccination. Across Britain, Germany and Sweden, the average number of smallpox deaths fell to record lows (the British averages were actually higher than usual due to an epidemic in the early 1890s), while in Central and Western Europe, where compulsory or enforced vaccination was relatively new, many countries had smallpox death rates per million inhabitants below 100. Vaccination was encouraged in Russia and Spain during this time (mandatory smallpox vaccination was not introduced until 1919 and 1921 respectively), and their average smallpox death rates greatly surpassed those of other European countries in the 1890s.

The 3.5-million-word Victorian Anti-Vaccination Discourse Corpus (hereon VicVaDis) is intended to provide a (freely accessible) historical resource for the investigation of the earliest public concerns and arguments against vaccination in England, which revolved around compulsory vaccination against smallpox in the second half of the 19th century. It consists of 133 anti-vaccination pamphlets and publications gathered from 1854 to 1906, a span of 53 years that loosely coincides with the Victorian era (1837-1901). This timeframe was chosen to capture the period between the 1853 Vaccination Act, which made smallpox vaccination for babies compulsory, and the 1907 Act which effectively ended the mandatory nature of vaccination.

The Quo VaDis project applies the latest techniques for large-scale computer-aided linguistic analysis to discussions about vaccinations in public discourse, and specifically in: social media discussions in English, UK Parliamentary debates and UK national press reports. The goal is to arrive at a better understanding of pro- and anti-vaccination views, as well as undecided views, which will inform future public health campaigns.

The project will be based in the world-renowned ESRC Centre for Corpus Approaches to Social Science (CASS) at Lancaster University, which was awarded a Queen's Anniversary Prize for Higher and Further Education in 2015. An interdisciplinary project team will work in interaction with three main project partners: Public Health England, the Department of Health and Social Care and the Department for Digital, Culture, Media & Sport.

The World Health Organization's (WHO) list of top ten global health threats includes 'vaccine hesitancy' - 'a delay in acceptance or refusal of vaccines despite availability of vaccination services'. Vaccination programmes are currently estimated to prevent between 2 and 3 million deaths a year worldwide. However, uptake of vaccinations in 90% of countries has been reported to be affected by vaccine hesitancy. In England, coverage for all routine childhood vaccinations is in decline, resulting in the resurgence of communicable diseases that had previously been eradicated. In August 2019, the UK lost its WHO measles elimination status.

The reasons for vaccine hesitancy are complex, but they need to be understood in order to be addressed effectively. This project focuses on discourse because the ways in which controversial topics such as vaccinations are talked about both reflect and shape beliefs and attitudes, which may in turn influence behaviour. More specifically, vaccinations have been the topic of UK parliamentary debates since before the first Vaccination Act of 1840; they have been increasingly discussed in the UK press since the early 1990s; and anti-vaccination views in particular have been described as part of a complex network of 'anti-public discourses' which, in recent years, are known to be both spread and contested on social media.

This project will involve the analysis of three multi-million-word datasets: (1) English-language contributions to three social media platforms: Mumsnet, Reddit and Twitter since the inception of each platform - respectively, 2000, 2005 and 2006; (2) UK national newspapers since 1990; and (3) UK parliamentary debates since 1830. These datasets will be analysed in a data-driven fashion by means of the computer-aided methods associated with Corpus Linguistics - a branch of Linguistics that involves the construction of large digital collections of naturally-occurring texts (known as 'corpora') and their analysis through tailor-made software. A corpus linguistic approach makes it possible to combine in a principled way the quantitative analysis of corpora containing millions of words with the qualitative analysis of individual texts, patterns and interactions. In this way, we will identify and investigate the different ways in which views about vaccinations are expressed in our data, for example, through patterns in choices of vocabulary, pronouns, negation, evaluation, metaphors, narratives, sources of evidence, and argumentation. We will reveal both differences and similarities in pro- and anti-vaccination views over time and across different groups of people, particularly as they form and interact on social media.

Our findings will make a major contribution to an understanding of views about vaccinations both in the UK (via our parliamentary and news datasets) and internationally (via our social media datasets). Through the involvement of our Project Partners, as well as more general engagement activities, these findings will be used as evidence for the design of future public health campaigns about vaccinations.

In nineteenth century Belgium, smallpox vaccination was available but was never made compulsory. For this reason, the number of deaths due to smallpox fluctuated regularly (although data before 1864 is scarce*), and the Great Pandemic of the 1870s caused the number of smallpox deaths in Belgium to skyrocket to 4.2 thousand per million people in 1871. Several sources suggest that smallpox had a similar impact in the Netherlands throughout the early and mid-1800s, however the Netherlands introduced mandatory vaccination for all children who were to be enrolled in school in 1873, and following the Great Pandemic the Netherlands' death rate was much lower than that of Belgium. The last natural case of smallpox was recorded in the Netherlands in 1900 (making it the fourth country in the world to eradicate the disease on a national level), while the last endemic case of smallpox in Belgium occurred in 1926. Data for Italy and Hungary is also scarce throughout the century, however Hungary introduced mandatory vaccination and revaccination in 1887, while Italy did the same in 1888; over the next decade we can see that the average number of smallpox deaths in these countries decreased greatly, and endemic cases of smallpox were eliminated in Hungary in 1923, and in 1947 in Italy.

Attitudes on vaccination against COVID-19. Topics: preferred time for getting vaccinated; importance of each of the following issues with regard to getting vaccinated: vaccine will help to end the pandemic, vaccine will protect respondent from getting COVID-19, vaccine will protect relatives and others from getting COVID-19, vaccine will make it possible to resume a more normal professional life, vaccine will make it possible to travel, vaccine will make it possible to meet family and friends, vaccine will make it possible to go to restaurants, cinemas etc.; importance of each of the following issues with regard to not getting vaccinated: pandemic will be over soon, personal risk of being infected is very low, risk posed by COVID-19 in general is exaggerated, worries about side effects of COVID-19 vaccines, vaccines have not been sufficiently tested yet, vaccines are ineffective, against vaccines in general; factors to increase personal willingness of getting vaccinated: more people around doing it, more people have already been vaccinated and we see that there are no major side-effects, people that recommend the vaccines are vaccinated themselves, doctor recommends respondent to do so, vaccines are developed in the European Union, full clarity on how vaccines are being developed, tested and authorized, respondent is very eager to get vaccinated or is already vaccinated, won’t get vaccinated anyway; attitude towards the following statements on the vaccines: benefits outweigh possible risks, vaccines authorised in the European Union are safe, vaccines are being developed, tested and authorised too quickly to be safe, vaccines could have long term side-effects that we do not know yet, a vaccine is the only way to end the pandemic, no understanding why people are reluctant to get vaccinated, serious diseases have disappeared thanks to vaccines; attitude towards the following statements: one can avoid being infected without being vaccinated, public authorities are not sufficiently transparent about COVID-19 vaccines, getting vaccinated against COVID-19 is a civic duty, vaccination should be compulsory, European Union is playing a key role in ensuring access to COVID-19 vaccines in the own country; most trustworthy institutions or persons regarding the provision of information about COVID-19 vaccines; interest in additional information about the following aspects: development, testing, and authorization of COVID-19 vaccines, safety of COVID-19 vaccines, effectiveness of COVID-19 vaccines; satisfaction with the handling of the vaccination strategy by: national government, EU; applicability of the following statements: respondent knows people who have tested positive to COVID-19, respondent knows people who have been ill because of COVID-19, respondent has tested positive to COVID-19, respondent has been ill because of COVID-19, respondent fears to be infected in the future; vaccination of respondent: as a child, as an adult; attitude towards vaccines in general: are safe, are effective. Demography: age; sex; nationality; age at end of education; occupation; professional position; type of community; household composition and household size; region. Additionally coded was: respondent ID; country; device used for interview; nation group; weighting factor. Einstellungen zur Impfung gegen Covid-19. Themen: präferierter Impfzeitpunkt; Wichtigkeit der folgenden Gründe im Hinblick auf die Entscheidung, sich impfen zu lassen: Impfstoff wird bei der Beendigung der Pandemie helfen, Impfstoff wird den/die Befragte/n vor Covid-19 schützen, Impfstoff wird Verwandte und andere vor COVID-19 schützen, Impfstoff wird wieder ein normaleres Berufsleben ermöglichen, Impfstoff wird das Reisen ermöglichen, Impfstoff wird Treffen mit Familie und Freunden ermöglichen, Impfstoff wird Restaurantbesuche und andere Aktivitäten wieder ermöglichen; Wichtigkeit der folgenden Gründe im Hinblick auf die Entscheidung, sich nicht impfen zu lassen: Pandemie wird bald vorbei sein, persönliches Infektionsrisiko ist sehr gering, Risiko durch COVID-19 ist allgemein übertrieben, Sorgen über die Nebenwirkungen von COVID-19-Impfstoffen, Impfstoffe sind noch nicht ausreichend getestet, Impfstoffe sind unwirksam, generelle Ablehnung von Impfungen; Faktoren, die die persönliche Impfbereitschaft erhöhen würden: mehr geimpfte Menschen im Umfeld, viele erfolgreich geimpfte Menschen ohne gravierende Nebenwirkungen, Menschen, die die Impfung empfehlen, sind selbst geimpft, Empfehlung des eigenen Arztes, Entwicklung der Impfstoffe in der Europäischen Union, vollständige Klarheit über Entwicklung, Testung und Zulassung der Impfstoffe, starker Wunsch nach einer Impfung bzw. Befragte/r ist bereits geimpft, keine Impfung geplant; Einstellung zu den folgenden Aussagen zu den Impfstoffen: Vorteile überwiegen mögliche Risiken, in der EU zugelassene Impfstoffe sind sicher, zu schnelle Entwicklung, Testung und Zulassung der Impfstoffe, um sicher zu sein, noch unbekannte potentielle Langzeit-Nebenwirkungen, Impfung ist die einzige Möglichkeit zur Beendigung der Pandemie, kein Verständnis für Impfgegner, Ausrottung ernsthafter Krankheiten durch Impfung; Einstellung zu den folgenden Aussagen: Ansteckung kann auch ohne Impfung vermieden werden, mangelnde Transparenz öffentlicher Behörden in Bezug auf die Corona-Impfstoffe, Impfung gegen COVID-19 ist Bürgerpflicht, Impfung sollte verpflichtend sein, Europäische Union spielt wesentliche Rolle bei der Versorgung des eigenen Landes mit Impfstoff; vertrauenswürdigste Institutionen oder Personen im Hinblick auf die Bereitstellung von Informationen über Corona-Impfstoffe; Interesse an zusätzlichen Informationen über die folgenden Aspekte: Entwicklung, Testung und Zulassung von COVID-19-Impfstoffen, Sicherheit von COVID-19- Impfstoffen, Effektivität von COVID-19-Impfstoffen; Zufriedenheit mit der Umsetzung der Impfstrategie durch: nationale Regierung, EU; Anwendbarkeit der folgenden Aussagen: Befragte/r kennt Menschen mit positivem Corona-Testergebnis, Befragte/r kennt Menschen mit Corona-Erkrankung, Befragte/r hatte positives Corona-Testergebnis, Befragte/r war an Corona erkrankt, Befragte/r fürchtet Ansteckung in der Zukunft; Impfung des/der Befragten als: Kind, Erwachsener; Einstellung zu Impfstoffen im allgemeinen: sind sicher, sind wirksam. Demographie: Alter; Geschlecht; Staatsangehörigkeit; Alter bei Beendigung der Ausbildung; Beruf; berufliche Stellung; Urbanisierungsgrad; Haushaltszusammensetzung und Haushaltsgröße; Region. Zusätzlich verkodet wurde: Befragten-ID; Land; für das Interview genutztes Gerät; Nationengruppe; Gewichtungsfaktor.

This statistic displays the percentage of the world population that has been vaccinated with select routine vaccinations as of 2022. According to the data, globally, just 51 percent of people have had a last Rota vaccine against the Rotavirus. Rotavirus is responsible for an inflammation of the intestines and stomach and causes severe gastrointestinal and diarrheal disease.

Vaccination success worldwide

All around the world, vaccinations have been effective in reducing the number of cases and deaths of various communicable diseases since the introduction of global vaccination programs in the 1970’s. For example, between 2000 and 2021, millions of deaths due to measles have been averted all over the globe. The final aim of vaccination is to eradicate the disease entirely, as is the case with smallpox: no cases have been reported since 1978.

Under-immunized groups

Despite the success of immunization programs, there are still groups lacking the recommended vaccinations; this is often due to a lack of access or resources within a country or region, although under-immunization can also be a result of hesitancy due to personal beliefs. Individual rights involving compulsory vaccinations has also remained a hot topic over the years- for example, support for government-required childhood vaccinations has decreased in the U.S. since 1991. In order to further grow vaccination coverage, targeted strategies are needed for under-immunized and vaccine-hesitant groups using context-specific interventions to increase and monitor immunization rates.

Vaccination against COVID-19 is making progress globally, but vaccine doses remain a rare commodity in many parts of the world. New virus variants mean that updated vaccines become available more slowly. Policymakers have defined criteria to regulate who gets priority access to the vaccination, such as age, health complications, or those who hold system-relevant jobs. But how does the public think about vaccine allocation? To explore those preferences, we surveyed respondents in Brazil, Germany, Italy, Poland, and the United States from September to December of 2020 using ranking and forced-choice tasks. We find that public preferences are consistent with expert guidelines prioritizing health care workers and people with medical preconditions. However, the public also considers those signing up early for vaccination and citizens of the country to be more deserving than later-comers and non-citizens. These results hold across measures, countries, and socio-demographic subgroups.

Measles is a highly contagious and severe disease. Despite mass vaccination, it remains a leading cause of death in children in developing regions, killing 114,900 globally in 2014. In 2006, China committed to eliminating measles by 2012; to this end, the country enhanced its mandatory vaccination programs and achieved vaccination rates reported above 95% by 2008. However, in spite of these efforts, during the last 3 years (2013–2015) China documented 27,695, 52,656, and 42,874 confirmed measles cases. How measles manages to spread in China—the world’s largest population—in the mass vaccination era remains poorly understood. To address this conundrum and provide insights for future public health efforts, we analyze the geospatial pattern of measles transmission across China during 2005–2014. We map measles incidence and incidence rates for each of the 344 cities in mainland China, identify the key socioeconomic and demographic features associated with high disease burden, and identify transmission clusters based on the synchrony of outbreak cycles. Using hierarchical cluster analysis, we identify 21 epidemic clusters, of which 12 were cross-regional. The cross-regional clusters included more underdeveloped cities with large numbers of emigrants than would be expected by chance (p = 0.011; bootstrap sampling), indicating that cities in these clusters were likely linked by internal worker migration in response to uneven economic development. In contrast, cities in regional clusters were more likely to have high rates of minorities and high natural growth rates than would be expected by chance (p = 0.074; bootstrap sampling). Our findings suggest that multiple highly connected foci of measles transmission coexist in China and that migrant workers likely facilitate the transmission of measles across regions. This complex connection renders eradication of measles challenging in China despite its high overall vaccination coverage. Future immunization programs should therefore target these transmission foci simultaneously.

Varicella Virus Vaccine Live Market Outlook

The global varicella virus vaccine live market is witnessing significant growth, with a market size valued at approximately USD 3.5 billion in 2023 and projected to reach USD 5.9 billion by 2032, growing at a robust CAGR of 6.2% during the forecast period. This upward trajectory is primarily driven by the increasing prevalence of varicella-zoster virus infections and the growing awareness regarding vaccination programs worldwide. Additionally, the expansion of immunization schedules and the rise in healthcare expenditure are contributing factors to the market's growth.

One of the primary drivers of growth in this market is the increasing global awareness of the importance of vaccination in preventing infectious diseases. With the World Health Organization and various governmental health agencies promoting immunization programs, there is a greater emphasis on preventing diseases like chickenpox and herpes zoster through vaccination. The preventative nature of vaccines reduces the incidence of these diseases, which in turn lowers healthcare costs associated with treating varicella complications. Moreover, advancements in vaccine formulations and delivery mechanisms are making these vaccines more effective and accessible, thus boosting market growth.

Another significant driver is the demographic shift and the increasing geriatric population, particularly in developed countries. As individuals age, their immune systems weaken, making them more susceptible to infections like herpes zoster, also known as shingles. The demand for varicella vaccines is rising as part of preventative healthcare measures among the elderly. Additionally, pediatric vaccination rates are increasing due to mandatory immunization policies in several countries, further propelling the market's expansion. The combination of these demographic trends and government policies ensures a steady demand for varicella vaccines across various age groups.

Technological advancements in vaccine development are also playing a crucial role in market growth. Increased investment in research and development by pharmaceutical companies has led to the introduction of more potent and safer vaccine options. New vaccine formulations that offer longer-lasting immunity and fewer side effects are being developed and brought to market. Moreover, the advent of combination vaccines, which protect against multiple diseases with a single shot, is gaining popularity, particularly in regions with comprehensive immunization programs. This trend is expected to continue, driving further market expansion.

The Shingles Vaccine has become an essential tool in preventing herpes zoster, particularly among the aging population. As the immune system weakens with age, the risk of developing shingles increases, making vaccination a critical preventive measure. The introduction of the shingles vaccine has significantly reduced the incidence and severity of herpes zoster outbreaks, providing relief to millions of older adults. This vaccine not only helps in preventing the painful rash associated with shingles but also reduces the risk of complications such as postherpetic neuralgia. With healthcare providers increasingly recommending the shingles vaccine for adults over 50, its adoption is expected to rise, further driving market growth.

Regionally, North America and Europe currently dominate the varicella virus vaccine live market due to well-established healthcare systems and high awareness levels regarding vaccination. However, the Asia Pacific region is anticipated to witness the highest growth rate during the forecast period. This growth is attributed to the increasing population, rising disposable incomes, and government initiatives aimed at improving public health. Additionally, the expansion of healthcare infrastructure and increased focus on disease prevention in emerging economies are expected to boost the market in this region.

Product Type Analysis

The varicella virus vaccine live market is segmented by product type into monovalent and combination vaccines. Monovalent vaccines, which are specifically designed to protect against a single virus strain, constitute a significant portion of the market. These vaccines have been traditionally used for immunization against chickenpox, especially in pediatric populations. The efficacy and established safety profile of monovalent vaccines make them a preferred choice in many national immunization schedules. Moreover,

Re-emergence of pertussis despite high vaccination coverage in western countries, results in increased risk for severe and even fatal pertussis among newborns. For this reason, late 2015 the Dutch Health Council (HC) advised to offer 3rd trimester pertussis vaccination to pregnant women. At the start of the maternal pertussis programme late 2019, the maternal Tdap was advised from 22w of gestation onwards.

Preterms, accounting for 8% of newborns in the Netherlands, are at highest risk for severe pertussis leading to prolonged hospital and intensive care admissions and sometimes death. Recently, it has become evident that despite 3rd trimester vaccination, preterms remain at high risk because the vaccination is likely given too late for sufficient antibody transfer. For this vulnerable group 2nd trimester vaccination may offer better protection because of extended time for antibody transfer.

To date, most countries recommend 3rd trimester vaccination to protect young, not yet (fully) vaccinated infants. Data from England show 91% effectiveness against infant pertussis after maternal Tetanus- diphtheria -acellular Pertussis (Tdap) vaccination in the 3rd trimester.

Studies focussing on preterms and protection after maternal vaccination are scarce. Two observational studies reported on effectiveness and antibody levels in cord blood of 2nd trimester vaccination in term infants. While one study showed significantly higher antibody levels after 2nd trimester vaccination (13-25 gestational weeks; GW), another study showed decreased effectiveness of 2nd trimester (<27 GW) vaccination. Only one study concerned antibody transfer in preterms and reported higher antibody levels after 2nd (n=37) than after 3rd (n=48) trimester vaccination.

Aiming to contribute to setting optimal vaccine strategy of maternal pertussis vaccination in the Netherlands and elsewhere and particular for the most vulnerable group of preterms, we propose a study that compares pertussis antibody levels in preterms and terms after 2nd trimester maternal vaccination. We can compare these to data we have on 3rd trimester Tdap in terms. In addition to adequate antibody levels, success of 2nd trimester vaccination depends on acceptance of this strategy by pregnant women and professionals.

Our primary endpoint is IgG anti-pertussis toxin (Pt) antibody concentration in preterms and terms at 2m of age,

Pt is considered the most relevant antibody for protection against clinical pertussis. Secondary endpoints are e.g. pertussis specific antibody concentrations in preterms and terms in cord blood and in women at delivery. Determinants of acceptance of 2nd trimester maternal vaccination are also a secondary endpoint.

Antibody concentrations will be assessed in serum, using a fluorescent bead-based multiplex immunoassay, with required blood volume of minimal 100µl.

For the survey on acceptance, we aim to have 4 groups of 100 women each, i.e. women who are pregnant for the 1st time, women who already gave birth and in both groups women with and without a known increased risk of preterm delivery. For the immunogenicity part, we aim to have at least 60 preterms and 60 terms, as this is, according to experts, the minimum number to enable good comparisons.

Pregnant women will be offered 2nd trimester pertussis vaccination. Both among acceptors and non-acceptors acceptance of 2nd trimester vaccination will be assessed. Women are first asked to participate in the acceptance part after the 1st antenatal visit to a midwife or obstetrician. They fill in a questionnaire to assess behavioral determinants and beliefs that underlie acceptance of 2nd trimester maternal vaccination. Only after this consent, women will be asked to participate in the immunogenicity part. Hereby, women will receive Tdap after they have the 20w standard anomaly ultrasound scan (20-24 GW). Vaccinated women will be followed until delivery. All preterms and a random selection of 60 terms, all of vaccinated mothers, will be followed until 2m of age, i.e. just before start of the NIP. By including both women in primary and secondary antenatal care, we aim to enrich our study population with women who are at increased risk for preterm delivery, as these women are usually seen by an obstetrician.

Data from our study will determine whether 2nd trimester Tdap leads to sufficient Pt antibodiy concentration in terms and preterms compared to 3rd trimester vaccination. Furthermore, we will have knowledge about obstacles for acceptance and can tailor information for all pregnant women to overcome these. Finally, given that in near future besides pertussis other maternal vaccines are likely to become available for prevention of severe disease in newborns (RSV, GBS), in particular in preterms, this study generates essential knowledge for future vaccine policy of maternal vaccines.

Global HIV-1 genetic diversity forms a major obstacle to the development of an HIV vaccine. It may be necessary to employ subtype-specific HIV-1 vaccines in individual countries according to their HIV-1 subtype distribution. We estimated the global and regional need for subtype-specific HIV-1 vaccines. We took into account the proportions of different HIV-1 variants circulating in each country, the genetic composition of HIV-1 recombinants, and the different genome segments (gag, pol, env) that may be incorporated into vaccines. We modeled different scenarios according to whether countries would employ subtype-specific HIV-1 vaccines against (1) the most common subtype; (2) subtypes contributing more than 5% of HIV infections; or (3) all circulating subtypes. For therapeutic vaccines targeting the most common HIV-1 subtype in each country, 16.5 million doses of subtype C vaccine were estimated globally, followed by subtypes A (14.3 million) and B (4.2 million). A vaccine based on env required 2.6 million subtype E doses, and a vaccine based on pol required 4.8 million subtype G doses. For prophylactic vaccines targeting the most common HIV-1 subtype in each country, 1.9 billion doses of subtype A vaccine were estimated globally, followed by subtype C (1.1 billion) and subtype B (1.0 billion). A vaccine based on env required 1.2 billion subtype E doses, and a vaccine based on pol required 0.3 billion subtype G doses. If subtype-specific HIV-1 vaccines are also directed against less common subtypes in each country, vaccines targeting subtypes D, F, H, and K are also needed and would require up to five times more vaccine doses in total. We conclude that to provide global coverage, subtype-specific HIV-1 vaccines need to be directed against subtypes A, B, and C. Vaccines targeting env also need to include subtype E and those targeting pol need to include subtype G.

IntroductionEvidence is being consolidated that shows that the utilization of antenatal and immunization services has declined in low-income countries (LICs) during the COVID-19 pandemic. Very little is known about the effects of the pandemic on antenatal and immunization service utilization in The Gambia. We set out to explore the COVID-19-related factors affecting the utilization of antenatal and immunization services in two Local Government Areas (LGAs) in The Gambia.MethodsA qualitative methodology was used to explore patients’ and providers’ experiences of antenatal and immunization services during the pandemic in two LGAs in The Gambia. Thirty-one study participants were recruited from four health facilities, applying a theory-driven sampling framework, including health workers as well as female patients. Qualitative evidence was collected through theory-driven semi-structured interviews, and was recorded, translated into English, transcribed, and analysed thematically, applying a social-ecological framework.ResultsIn our interviews, we identified themes at five different levels: individual, interpersonal, community, institutional and policy factors. Individual factors revolved around patients’ fear of being infected in the facilities, and of being quarantined, and their anxiety about passing on infections to family members. Interpersonal factors involved the reluctance of partners and family members, as well as perceived negligence and disrespect by health workers. Community factors included misinformation within the community and mistrust of vaccines. Institutional factors included the shortage of health workers, closures of health facilities, and the lack of personal protective equipment (PPEs) and essential medicines. Finally, policy factors revolved around the consequences of COVID-19 prevention measures, particularly the shortage of transport options and mandatory wearing of face masks.ConclusionsOur findings suggest that patients’ fears of contagion, perceptions of poor treatment in the health system, and a general anxiety around the imposing of prevention measures, undermined the uptake of services. In future emergencies, the government in The Gambia, and governments in other LICs, will need to consider the unintended consequences of epidemic control measures on the uptake of antenatal and immunization services.

As COVID-19 continues to circulate in Canada and more people are getting vaccinated, different public health measures (PHMs) may be required, based on the level of transmission and other key indicators outlined below. This interim guidance provides considerations for adjusting PHMs in the context of COVID-19 vaccination in Canada. Governments and public health authorities (PHAs) across the country need to plan for these adjustments, as vaccination coverage increases in the population, the number of new and active cases decreases, and as pressures on the healthcare system and public health ease.

Aquaculture Vaccines Market Size And Forecast

Aquaculture Vaccines Market size was valued at 223.84 USD Million in 2023 and is projected to reach 337.27 USD Million by 2030, growing at a CAGR of 5.80% during the forecast period 2024-2030.

Global Aquaculture Vaccines Market Drivers

The market drivers for the Aquaculture Vaccines Market can be influenced by various factors. These may include:

Growing Consumer: Preference for Healthful, High-Protein Diets and the growing world population are pushing up demand for seafood. To guarantee healthy fish stocks, this is in turn making the demand for efficient aquaculture methods—including vaccination—even greater.

Growing Incidence of Aquatic Diseases: There is serious worry about the frequency of infectious diseases in farmed fish and other aquatic creatures. By helping to stop and manage outbreaks, vaccines lower the death rates and financial losses associated with aquaculture.

Vaccine Technology Advancements: Vaccines for different aquatic animals are being developed more successfully and specifically thanks to advances in immunology and biology. Vaccine efficacy and uptake are being increased via better formulations, delivery systems, and adjuvants.

Government Initiatives and Regulatory Support: The application of vaccines is one of the sustainable aquaculture techniques being promoted by several governments and regulatory agencies. Vaccination programmes are being promoted by policies and subsidies that support aquaculture health management.

Environmental Issues and Sustainability: Sustainable aquaculture methods are becoming more and more important in order to reduce environmental effect. The objectives of environmentally friendly and sustainable aquaculture are aligned with the requirement for vaccination in lowering the demand for antibiotics and other chemical treatments.

Economic Benefits: By cutting mortality, minimising the need for medical care, and raising feed conversion ratios, vaccination in aquaculture can result in substantial cost savings. Better profitability for farmers and increased outputs are results of healthier fish populations.

Consumer Knowledge and Preference: As consumers become more knowledgeable about the safety and quality of food, the aquaculture sector is being forced to implement methods that guarantee seafood is free of diseases. Meeting these customer expectations mostly depends on vaccinations.

Growing Aquaculture operations: The need for vaccinations is being driven by the growing aquaculture operations in both developed and developing countries. Vaccines are one of the many efficient health management options that are becoming more and more needed as aquaculture operations expand and new species are farmed.

Partnerships: among research organisations, vaccine producers, and aquaculture businesses are promoting the creation of novel vaccinations. Working together, research is moving more quickly and cutting-edge vaccines are hitting the market.

The complete COVID-19 dataset is a collection of the COVID-19 data maintained by Our World in Data that is updated throughout the duration of COVID-19. It includes information related to confirmed cases and deaths, hospitalization, intensive care unit admissions, testing for COVID-19, and vaccination for COVID-19.Confirmed cases and deaths: this data is collected from the World Health Organization Coronavirus Dashboard. The cases & deaths dataset is updated daily.Note 1: Time/date stamps reflect when the data was last updated by WHO. Due to the time required to process and validate the incoming data, there is a delay between reporting to WHO and the update of the dashboard.Note 2: Counts and corrections made after these times will be carried forward to the next reporting cycle for that specific region. Delayed reporting for any specific country, territory or area may result in pooled counts for multiple days being presented, with a retrospective update to counts on previous days to accurately reflect trends. Significant data errors detected or reported to WHO may be corrected at more frequent intervals.Hospitalizations and intensive care unit (ICU) admissions: our data is collected from official sources and collated by Our World in Data. The complete list of country-by-country sources is available here.Testing for COVID-19: this data is collected by the Our World in Data team from official reports; you can find further details in our post on COVID-19 testing, including our checklist of questions to understand testing data, information on geographical and temporal coverage, and detailed country-by-country source information. On 23 June 2022, we stopped adding new datapoints to our COVID-19 testing dataset. You can read more here.Vaccinations against COVID-19: this data is collected by the Our World in Data team from official reports.Other variables: this data is collected from a variety of sources (United Nations, World Bank, Global Burden of Disease, Blavatnik School of Government, etc.). More information is available in our codebook.

The Great Smallpox Pandemic of 1870 to 1875 was the last major smallpox epidemic to reach pandemic level across Europe. The outbreak has its origins in the Franco-Prussian War of 1870 to 1871, where unvaccinated French prisoners of war infected the German civilian population, before the virus then spread to all corners of Europe. The death rates peaked in different years for individual countries; with the highest numbers recorded in 1871 for the German states, Belgium and the Netherlands, while death rates peaked in Austria, Scotland and Sweden in later years (the states that peaked in 1871 were closer in proximity to the frontlines of the Franco-Prussian War). Impact of compulsory vaccination The average number of deaths per million people was much higher in countries without compulsory vaccination, ranging from 953 to 1,360 in the samples given here. In comparison to this, the countries with compulsory vaccination barely reached these numbers in the years when the epidemic was at its worst, and their annual averages ranged between 314 and 361 deaths per million people during the six years shown here. Impact of the Great Pandemic Following the surge in smallpox deaths caused by the pandemic, many of the countries listed here introduced mandatory vaccination, or introduced penalties for parents who did not vaccinate their children. Germany and the Netherlands** did this in 1874, while Britain and Sweden enforced their vaccination laws with stricter penalties in 1871 and 1880 respectively. Perhaps surprisingly, Austria and Belgium, the two countries with the highest average death rate shown here, never introduced mandatory smallpox vaccination.

Objective: To estimate the prevalence of missed opportunities for vaccination (MOV) among children aged 0–23 months attending health-care facilities in Africa and explore the factors responsible for MOV using systems thinking. Research design and methods: We conducted a systematic review and meta-analysis of studies reporting the proportion MOVs. Five electronic databases were searched. A random effects model was fitted to obtain pooled estimates of MOV and a causal loop diagram (CLD) was constructed to explore the dynamics of the causes of MOV. MOV was defined as any contact with health services in Africa, by an unvaccinated or under-vaccinated child, aged 0–23 months, who is eligible for vaccination and free of any contraindication, which does not result in vaccination. Results: Four hundred and twenty-one publications were found, of which 20 studies from 14 countries were included. The pooled prevalence of MOV was estimated to be 27.26% (95%CI: 18.80–36.62). A CLD with seven reinforcing and two balancing loops were constructed. Conclusion: Our findings suggest that about one in every four children under the age of two years who visited health facilities in 14 African countries missed the vaccination they were eligible to receive. To enable continent-wide estimates, more MOV assessments are required.